Fanconi Syndrome Due to Deferasirox

American Journal of Kidney Diseases

Volumn 54, Issue 5, 2009, Pages 931-934

  Rafat, Cédric ^a,b   Fakhouri, Fadi ^a,b   Ribeil, Jean Antoine ^a,b   Delarue, Richard ^a,b   Le Quintrec, Moglie ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Deferasirox; Fanconi syndrome; iron; renal toxicity

Indexed keywords

CREATININE; DEFERASIROX; DEFERIPRONE; ERYTHROPOIETIN; GLIBENCLAMIDE; METFORMIN; PERINDOPRIL;

ACUTE KIDNEY FAILURE; AGED; ARTICLE; CASE REPORT; CLINICAL FEATURE; CREATININE BLOOD LEVEL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; FANCONI RENOTUBULAR SYNDROME; GLOMERULUS FILTRATION; HUMAN; IRON CHELATION; IRON OVERLOAD; MALE; SIDEROBLASTIC ANEMIA;

AGED; BENZOIC ACIDS; FANCONI SYNDROME; HUMANS; IRON CHELATING AGENTS; MALE; TRIAZOLES;

EID: 70350003769     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2009.03.013     Document Type: Article

References (18)

1. Schrier S.L., and Angelucci E. New strategies in the treatment of the thalassemias. Annu Rev Med 56 (2005) 157-171
2. Sechaud R., Robeva A., Belleli R., and Balez S. Absolute oral bioavailability and disposition of deferasirox in healthy human subjects. J Clin Pharmacol 48 (2008) 919-925
3. Kontoghiorghes G.J. Ethical issues and risk/benefit assessment of iron chelation therapy: Advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox. Hemoglobin 32 (2008) 1-15
4. Jabbour E., Kantarjian H.M., Koller C., and Taher A. Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes. Cancer 112 (2008) 1089-1095
5. Neufeld E.J. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: New data, new questions. Blood 107 (2006) 3436-3441
6. Maggio A. Light and shadows in the iron chelation treatment of haematological diseases. Br J Haematol 138 (2007) 407-421
7. Delea T.E., Edelsberg J., Sofrygin O., et al. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: A literature review. Transfusion 47 (2007) 1919-1929
8. Bruin G.J., Faller T., Wiegand H., et al. Pharmacokinetics, distribution, metabolism, and excretion of deferasirox and its iron complex in rats. Drug Metab Dispos 36 (2008) 2523-2538
9. Cappellini M.D., Cohen A., Piga A., et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 107 (2006) 3455-3462
10. Yusuf B., McPhedran P., and Brewster U.C. Hypocalcemia in a dialysis patient treated with deferasirox for iron overload. Am J Kidney Dis 52 (2008) 587-590
11. Nick H., Acklin P., Lattmann R., et al. Development of tridentate iron chelators: From desferrithiocin to ICL670. Curr Med Chem 10 (2003) 1065-1076
12. Lindsey W.T., and Olin B.R. Deferasirox for transfusion-related iron overload: A clinical review. Clin Ther 29 (2007) 2154-2166
13. Kontoghiorghes G.J. Update on toxicity and efficacy aspects of treatment with deferasirox and its implication on the morbidity and mortality of transfused iron loaded patients. Expert Opin Drug Saf 7 (2008) 645-646
14. Vichinsky E. Clinical application of deferasirox: Practical patient management. Am J Hematol 83 (2008) 398-402
15. Clajus C., Becker J.U., Stichtenoth D.O., et al. Acute kidney injury due to deferoxamine in a renal transplant patient. Nephrol Dial Transplant 23 (2008) 1061-1064
16. Hider R.C., and Zhou T. The design of orally active iron chelators. Ann N Y Acad Sci 1054 (2005) 141-154
17. Kontoghiorghes G.J. Deferasirox: Uncertain future following renal failure fatalities, agranulocytosis and other toxicities. Expert Opin Drug Saf 6 (2007) 235-239
18. Vichinsky E., Onyekwere O., Porter J., et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol 136 (2007) 501-508